Sep 27, 2021 / 02:40PM GMT
Alethia Rene Young - Cantor Fitzgerald & Co., Research Division - Director of Equity Research & Head of Healthcare Research
Hi, everybody, it's Alethia Young here. I cover large-cap, small, mid-cap at Cantor, biotech, of course. Very happy to have TG Therapeutics. I have Mike Weiss, who's the Chairman, President and CEO. So we'll do a fireside chat for the next little bit. There's a lot to talk about. So maybe we'll just dive into like, obviously, launch the drug -- well, you know what, Mike, why don't you just level set for 30 seconds or so, and then we'll go into the questions, so that everybody is on the same page.
Michael S. Weiss - TG Therapeutics, Inc. - Chairman, CEO & President
Yes. Sure. So first, thanks for having us for the conference, as always. It's nice to see you. Yes. Just a quick background around TG. For those of you who are not familiar with the company, we're a B-cell-focused company with big programs in B-cell malignancies and B-cell disorders. So on B-cell malignancy side, we have chronic lymphocytic leukemia, marginal zone
TG Therapeutics Inc at Cantor Fitzgerald Global Healthcare Conference (Virtual) Transcript
Feb 09, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers